Erosive Esophagitis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
The 7 major erosive esophagitis markets are expected to exhibit a CAGR of 19.2% during 2024-2034.
The erosive esophagitis market has been comprehensively analyzed in IMARC's new report titled "Erosive Esophagitis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Erosive esophagitis is a medical condition characterized by inflammation, irritation, and erosion of the lining of the esophagus, which is the muscular tube that carries liquid and food from the mouth to the stomach. The most common symptom of this ailment is discomfort or burning sensations in the chest, which may be worse after eating, lying down, or bending over. Numerous other indications of the illness include regurgitation of food, difficulty swallowing, nausea, vomiting, chronic cough, a sour taste in the mouth, etc. The severity of these symptoms might vary from mild discomfort to more severe pain and complications. Diagnosing erosive esophagitis typically requires a combination of the patient's medical history, characteristic findings, and physical examination. A healthcare provider may also perform an upper endoscopy, in which a flexible, thin tube with a camera at its tip is inserted through the mouth to directly visualize any inflammation or irritation in the esophageal lining. Several other diagnostic studies, such as barium swallow workup, pH monitoring test, tissue biopsy, etc., may be utilized to assess the severity of the condition and its underlying causes.
The rising cases of chronic gastroesophageal reflux disease, in which abdominal acid and bile flow back into the esophagus, leading to inflammation and irritation of the tissue, are primarily driving the erosive esophagitis market. In addition to this, the escalating prevalence of various associated risk factors, such as smoking, excessive alcohol intake, consumption of a high-fat diet, connective tissue disorders, obesity, etc., is creating a positive outlook for the market. Moreover, the widespread adoption of proton pump inhibitors, including omeprazole and lansoprazole, to reduce the production of stomach acid and improve the quality of life for individuals suffering from erosive esophagitis is further bolstering the market growth. Apart from this, the inflating application of endoscopic mucosal resection procedures, since they involve the removal of abnormal or damaged tissue from the lining of the gastrointestinal tract, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of mucosal protectants that form a protective barrier on the surface of the esophagus, thereby reducing irritation and aiding in the healing process, is expected to drive the erosive esophagitis market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the erosive esophagitis market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for erosive esophagitis and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the erosive esophagitis market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the erosive esophagitis market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the erosive esophagitis market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current erosive esophagitis marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the erosive esophagitis market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the erosive esophagitis market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the erosive esophagitis market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of erosive esophagitis across the seven major markets?
What is the number of prevalent cases (2018-2034) of erosive esophagitis by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of erosive esophagitis by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with erosive esophagitis across the seven major markets?
What is the size of the erosive esophagitis patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of erosive esophagitis?
What will be the growth rate of patients across the seven major markets?
Erosive Esophagitis: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for erosive esophagitis drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the erosive esophagitis market?
What are the key regulatory events related to the erosive esophagitis market?
What is the structure of clinical trial landscape by status related to the erosive esophagitis market?
What is the structure of clinical trial landscape by phase related to the erosive esophagitis market?
What is the structure of clinical trial landscape by route of administration related to the erosive esophagitis market?
The erosive esophagitis market has been comprehensively analyzed in IMARC's new report titled "Erosive Esophagitis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Erosive esophagitis is a medical condition characterized by inflammation, irritation, and erosion of the lining of the esophagus, which is the muscular tube that carries liquid and food from the mouth to the stomach. The most common symptom of this ailment is discomfort or burning sensations in the chest, which may be worse after eating, lying down, or bending over. Numerous other indications of the illness include regurgitation of food, difficulty swallowing, nausea, vomiting, chronic cough, a sour taste in the mouth, etc. The severity of these symptoms might vary from mild discomfort to more severe pain and complications. Diagnosing erosive esophagitis typically requires a combination of the patient's medical history, characteristic findings, and physical examination. A healthcare provider may also perform an upper endoscopy, in which a flexible, thin tube with a camera at its tip is inserted through the mouth to directly visualize any inflammation or irritation in the esophageal lining. Several other diagnostic studies, such as barium swallow workup, pH monitoring test, tissue biopsy, etc., may be utilized to assess the severity of the condition and its underlying causes.
The rising cases of chronic gastroesophageal reflux disease, in which abdominal acid and bile flow back into the esophagus, leading to inflammation and irritation of the tissue, are primarily driving the erosive esophagitis market. In addition to this, the escalating prevalence of various associated risk factors, such as smoking, excessive alcohol intake, consumption of a high-fat diet, connective tissue disorders, obesity, etc., is creating a positive outlook for the market. Moreover, the widespread adoption of proton pump inhibitors, including omeprazole and lansoprazole, to reduce the production of stomach acid and improve the quality of life for individuals suffering from erosive esophagitis is further bolstering the market growth. Apart from this, the inflating application of endoscopic mucosal resection procedures, since they involve the removal of abnormal or damaged tissue from the lining of the gastrointestinal tract, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of mucosal protectants that form a protective barrier on the surface of the esophagus, thereby reducing irritation and aiding in the healing process, is expected to drive the erosive esophagitis market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the erosive esophagitis market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for erosive esophagitis and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the erosive esophagitis market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the erosive esophagitis market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the erosive esophagitis market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current erosive esophagitis marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the erosive esophagitis market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the erosive esophagitis market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the erosive esophagitis market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of erosive esophagitis across the seven major markets?
What is the number of prevalent cases (2018-2034) of erosive esophagitis by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of erosive esophagitis by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with erosive esophagitis across the seven major markets?
What is the size of the erosive esophagitis patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of erosive esophagitis?
What will be the growth rate of patients across the seven major markets?
Erosive Esophagitis: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for erosive esophagitis drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the erosive esophagitis market?
What are the key regulatory events related to the erosive esophagitis market?
What is the structure of clinical trial landscape by status related to the erosive esophagitis market?
What is the structure of clinical trial landscape by phase related to the erosive esophagitis market?
What is the structure of clinical trial landscape by route of administration related to the erosive esophagitis market?
1 PREFACE
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 EROSIVE ESOPHAGITIS - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 EROSIVE ESOPHAGITIS - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 EROSIVE ESOPHAGITIS - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 EROSIVE ESOPHAGITIS - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 EROSIVE ESOPHAGITIS - UNMET NEEDS
10 EROSIVE ESOPHAGITIS - KEY ENDPOINTS OF TREATMENT
11 EROSIVE ESOPHAGITIS - MARKETED PRODUCTS
11.1 List of Erosive Esophagitis Marketed Drugs Across the Top 7 Markets
11.1.1 Dexilant (Dexlansoprazole) - Takeda
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Nexium (Esomeprazole) - AstraZeneca
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
11.1.3 Protonix (Pantoprazole) - Takeda
11.1.3.1 Drug Overview
11.1.3.2 Mechanism of Action
11.1.3.3 Regulatory Status
11.1.3.4 Clinical Trial Results
11.1.3.5 Sales Across Major Markets
11.1.4 Prilosec (Omeprazole) - AstraZeneca/Mitsubishi Tanabe Pharma Corporation
11.1.4.1 Drug Overview
11.1.4.2 Mechanism of Action
11.1.4.3 Regulatory Status
11.1.4.4 Clinical Trial Results
11.1.4.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 EROSIVE ESOPHAGITIS - PIPELINE DRUGS
12.1 List of Erosive Esophagitis Pipeline Drugs Across the Top 7 Markets
12.1.1 X 842 - Cinclus Pharma
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. EROSIVE ESOPHAGITIS - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. EROSIVE ESOPHAGITIS – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 EROSIVE ESOPHAGITIS - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Erosive Esophagitis - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Erosive Esophagitis - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Erosive Esophagitis - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Erosive Esophagitis - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Erosive Esophagitis - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Erosive Esophagitis - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Erosive Esophagitis - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Erosive Esophagitis - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Erosive Esophagitis - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Erosive Esophagitis - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Erosive Esophagitis - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Erosive Esophagitis - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Erosive Esophagitis - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Erosive Esophagitis - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Erosive Esophagitis - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Erosive Esophagitis - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Erosive Esophagitis - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Erosive Esophagitis - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Erosive Esophagitis - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Erosive Esophagitis - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Erosive Esophagitis - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Erosive Esophagitis - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Erosive Esophagitis - Access and Reimbursement Overview
16 EROSIVE ESOPHAGITIS - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 EROSIVE ESOPHAGITIS MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 EROSIVE ESOPHAGITIS MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 EROSIVE ESOPHAGITIS - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 EROSIVE ESOPHAGITIS - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 EROSIVE ESOPHAGITIS - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 EROSIVE ESOPHAGITIS - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 EROSIVE ESOPHAGITIS - UNMET NEEDS
10 EROSIVE ESOPHAGITIS - KEY ENDPOINTS OF TREATMENT
11 EROSIVE ESOPHAGITIS - MARKETED PRODUCTS
11.1 List of Erosive Esophagitis Marketed Drugs Across the Top 7 Markets
11.1.1 Dexilant (Dexlansoprazole) - Takeda
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Nexium (Esomeprazole) - AstraZeneca
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
11.1.3 Protonix (Pantoprazole) - Takeda
11.1.3.1 Drug Overview
11.1.3.2 Mechanism of Action
11.1.3.3 Regulatory Status
11.1.3.4 Clinical Trial Results
11.1.3.5 Sales Across Major Markets
11.1.4 Prilosec (Omeprazole) - AstraZeneca/Mitsubishi Tanabe Pharma Corporation
11.1.4.1 Drug Overview
11.1.4.2 Mechanism of Action
11.1.4.3 Regulatory Status
11.1.4.4 Clinical Trial Results
11.1.4.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 EROSIVE ESOPHAGITIS - PIPELINE DRUGS
12.1 List of Erosive Esophagitis Pipeline Drugs Across the Top 7 Markets
12.1.1 X 842 - Cinclus Pharma
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. EROSIVE ESOPHAGITIS - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. EROSIVE ESOPHAGITIS – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 EROSIVE ESOPHAGITIS - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Erosive Esophagitis - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Erosive Esophagitis - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Erosive Esophagitis - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Erosive Esophagitis - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Erosive Esophagitis - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Erosive Esophagitis - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Erosive Esophagitis - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Erosive Esophagitis - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Erosive Esophagitis - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Erosive Esophagitis - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Erosive Esophagitis - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Erosive Esophagitis - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Erosive Esophagitis - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Erosive Esophagitis - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Erosive Esophagitis - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Erosive Esophagitis - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Erosive Esophagitis - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Erosive Esophagitis - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Erosive Esophagitis - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Erosive Esophagitis - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Erosive Esophagitis - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Erosive Esophagitis - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Erosive Esophagitis - Access and Reimbursement Overview
16 EROSIVE ESOPHAGITIS - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 EROSIVE ESOPHAGITIS MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 EROSIVE ESOPHAGITIS MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
